“Among patients treated for an occluded CVC, alteplase-treated patients had lower daily and total postocclusion costs than patients receiving catheter replacement.” Ernst et al (2014).
Ernst, F.R., Chen, E., Lipkin, C., Tayama, D. and Amin, A.N. (2014) Comparison of hospital length of stay, costs, and readmissions of alteplase versus catheter replacement among patients with occluded central venous catheters. Journal of Hospital Medicine. May 14th. .
Techniques to resolve occluded central venous catheters http://ctt.ec/C22fa+ @ivteam #ivteam
BACKGROUND: Central venous catheter (CVC) occlusion is common, affecting 30% of all CVCs.
OBJECTIVE: To compare length of stay (LOS), costs, and readmissions associated with the use of alteplase to clear catheter blockage to outcomes associated with catheter replacement.
DESIGN: Retrospective observational study utilizing a large hospital database.
PARTICIPANTS: Hospitalized patients treated for catheter occlusion from January 2006 to December 2011.
MAIN MEASURES: Univariate analyses of patient characteristics and treatment patterns and multivariable regression analyses of postocclusion hospital costs, LOS, and 30- and 90-day readmissions were conducted.
KEY RESULTS: We included 34,579 patients treated for a CVC occlusion by replacement (N = 1028) or by alteplase (2 mg) administration (N = 33,551). Patients receiving alteplase were somewhat younger than those having catheter replacement (60 ± 19 vs 62 ± 20 years old, P = 0.0002). After adjusting for patient and hospital factors via regression modeling, average daily postocclusion costs were $317 lower for alteplase recipients than for catheter replacement patients (95% confidence interval [CI]: 238.22-392.24; P < 0.0001). Adjusted total postocclusion costs were $1419 lower for alteplase recipients versus patients receiving catheter replacement (95% CI: 307.27-2458.12; P = 0.0121). Postocclusion operating room/surgery, radiology, and supply costs were significantly lower for alteplase recipients (P < 0.001). Average adjusted postocclusion LOS was similar for both groups (P > 0.05). Odds of readmission were not significantly different at 30 or 90 days.
CONCLUSIONS: Among patients treated for an occluded CVC, alteplase-treated patients had lower daily and total postocclusion costs than patients receiving catheter replacement. Cost differences were mainly driven by lower operating room/surgery, radiology, and supplier costs.
Other intravenous and vascular access resources that may be of interest (External links – IVTEAM has no responsibility for content).
- Guide for intravenous chemotherapy and associated vascular access devices from Macmillan.
- CancerUK IV chemotherapy information.